CLOs on the Move

GPB Scientific

www.gpbscientific.com

 
GPB Scientific is transforming the process of purifying and enriching cells for cell therapy production. Reliable cell recovery and expansion are fundamental to the successful scale up of CAR-T or any therapeutic cell manufacturing process. GPB has developed a high-throughput, automatable, microfluidic closed-system for leukapheresis sample preparation and downstream processing of cells for CAR-T and other cell therapy production. This breakthrough reduces cell losses and skill-intensive manual steps.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

IQSynthesis

IQSynthesis is a Saint Louis, MO-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Argene SA

Argene SA is a Massapequa, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Reneo Pharmaceuticals

Reneo is a clinical stage pharmaceutical company focused on the development of therapies for patients with genetic mitochondrial diseases. Many of these diseases are associated with deficits in cellular metabolism and energy production. Our goal is to improve daily function and quality of life of patients suffering from these diseases, most specifically, by improving how their mitochondria work, preserving muscle function and preventing muscle injury, weakness and wasting.

Evelo Biosciences

Evelo Biosciences is dedicated to improving the lives of patients globally through the development of a new modality of medicines – monoclonal microbials. Monoclonal microbials are orally delivered medicines that modulate systemic immunology and biology through direct interactions with human cells in the gut. These new medicines are broadly applicable across many diseases – including autoimmune, immunoinflammatory, metabolic, neurological, neuroinflammatory diseases and cancer. Monoclonal microbials have the potential to fundamentally change traditional models of drug discovery and development. By finding and selecting naturally occurring monoclonal microbials with defined therapeutic effects, Evelo can improve the speed, cost and success of drug discovery and development. Evelo`s platform enables pharmacological intervention at all stages of disease with naturally occurring, safe and effective monoclonal microbials. Evelo Biosciences was conceived and created within VentureLabs®, Flagship Pioneering`s institutional innovation foundry, and launched by Flagship in 2015.

Virtual Incision

Virtual Incision Corporation is a privately-held medical device company focused on developing an advanced, miniaturized robot for general surgery abdominal procedures, such as colon resections. Propelled by the knowledge that colorectal and lower gastrointestinal procedures are the fastest growing in the United States, Dr. Dmitry Oleynikov and Dr. Shane Farritor founded Virtual Incision in 2006. The company is a spin-out of the University of Nebraska, where Dr. Dmitry Oleynikov and Dr. Shane Farritor are currently based. John Murphy joined Virtual Incision in 2012 and is based in Pleasanton, California.